Amish Chaturvedi is an experienced market access professional with 26 years of experience in the Pharmaceutical industry including in Pricing, Market access, Reimbursement and Policy across EU and JAPAC region. At EVERSANA, he leads Pricing and Market Access practice for the APAC region. As a practice lead, Amish leverages his vast experience to support pharmaceutical, medical devices and biotech companies build Value and Access strategy for Asia-Pacific region including for key markets like Japan, China, India, South Korea, Taiwan and Australia. Amish has extensive experience in developing and optimizing value communication in the local context to improve relevance and impact on payers. In addition, Amish supports clients optimize their access and reimbursement strategies at a regional level and guides the development of HTA submissions at country level.   Prior to joining EVERSANA, Amish spent 15 years in Policy and Market Access functions as therapy area lead for Abbvie and Janssen in above country and affiliate level roles.  Amish has hands-on experience managing reimbursement submissions to multiple HTA agencies. He has a deep understanding of access policies in key European and Asia-Pacific markets and HTA requirements across JAPAC,EU4 and the UK. He has worked across multiple therapy areas including Oncology, Immunology, Neuroscience, Infectious Diseases and Vaccines. Amish holds a B-Pharm degree, MBA degree (Australian National University) and Health Economics degree from London School of Economics (LSE).

Managing Director And Publisher of BioPharmaDispatch. A former senior adviser to two Australian health ministers and a senior industry executive.

Liz de Somer was appointed CEO of Medicines Australia in 2018 and has steered the association through four changes in Government and a dynamic policy landscape. Liz is one of Australia’s leading policy experts on the pharmaceutical industry. She is widely regarded for her contributions to national policy development spanning two decades and has led successive Strategic Agreement negotiations with Industry and the Commonwealth.   Liz began her career as an Intensive Care nurse before undertaking post-graduate studies in Medical Science, leading her to work across drug development, clinical trials, regulatory affairs and market access in the pharmaceutical industry. Her commitment to improving the lives of patients has remained a consistent focus throughout Liz’s career.  Liz contributes her industry expertise to various expert committees providing advice to Government. She was appointed by the Minister for Health and Aged Care to the HTA Review Reference Committee in 2023 and sits on the CMO Health Climate Strategy Advisory Group, the Ministerial Roundtable on Procurement, and the National Reconstruction Fund’s Enabling Capabilities Industry Working Group.

Sharon Winton is the CEO and Director at Lymphoma Australia. She is a board member of the Lymphoma Coalition and has been a health consumer representative on a number of consumer stakeholder meetings in Australia and overseas. Sharon is also the chair of Co design working group that was formed as part of the strategic agreement between Medicines Australia and the Commonwealth to enhance engagement with consumers in the HTA process. Prior to her current role she worked with a private health insurance company in relationship and strategic management. Sharon is extremely passionate about ensuring all Australians have equitable access to information and medicines.